Proteogenomic characterisation of primary oral cancer unveils extracellular matrix remodelling and immunosuppressive microenvironment linked to lymph node metastasis

Keywords

lymph node metastasis / oral squamous cell carcinoma / single-cell analysis

References

[1] Johnson NW, Jayasekara P, Amarasinghe AA. Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontol 2000. 2011;57(1):19-37.

[2] Wang X, Xu J, Wang L, Liu C, Wang H. The role of cigarette smoking and alcohol consumption in the differentiation of oral squamous cell carcinoma for the males in China. J Cancer Res Ther. 2015;11(1):141-145.

[3] Ram H, Sarkar J, Kumar H, Konwar R, Bhatt ML, Mohammad S. Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg. 2011;10(2):132-137.

[4] Sharma A, Indu S, Gautami D, Sharma D. Oral squamous cell carcinoma (OSCC) in humans: etiological factors, diagnostic and therapeutic relevance. Res J Biotechnol. 2020;15:141-151.

[5] González-Moles M, Aguilar-Ruiz M, Ramos-García P. Challenges in the early diagnosis of oral cancer, evidence gaps and strategies for improvement: a scoping review of systematic reviews. Cancers (Basel). 2022;14(19):4967.

[6] Chow LQM. Head and neck cancer. N Engl J Med. 2020;382(1):60-72.

[7] Ho AS, Kim S, Tighiouart M, et al. Metastatic lymph node burden and survival in oral cavity cancer. J Clin Oncol. 2017;35(31):3601-3609.

[8] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33.

[9] Shaikh S, Yadav DK, Bhadresha K, Rawal RM. Integrated computational screening and liquid biopsy approach to uncover the role of biomarkers for oral cancer lymph node metastasis. Sci Rep. 2023;13(1):14033.

[10] Ghantous Y, Mozalbat S, Nashef A, et al. EMT dynamics in lymph node metastasis of oral squamous cell carcinoma. Cancers. 2024;16(6):1185.

[11] Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-142.

[12] Katsuno Y, Derynck R. Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family. Dev Cell. 2021;56(6):726-746.

[13] Banerjee S, Lo W-C, Majumder P, et al. Multiple roles for basement membrane proteins in cancer progression and EMT. Euro J Cell Biol. 2022;101(2):151220.

[14] Sticht C, Hofele C, Flechtenmacher C, et al. Amplification of Cyclin L1 is associated with lymph node metastases in head and neck squamous cell carcinoma (HNSCC). Br J Cancer. 2005;92(4):770-774.

[15] Dharavath B, Butle A, Pal A, et al. Role of miR-944/MMP10/AXL-axis in lymph node metastasis in tongue cancer. Commun Biol. 2023;6(1):57.

[16] Liu S, Liu L, Ye W, et al. High vimentin expression associated with lymph node metastasis and predicated a poor prognosis in oral squamous cell carcinoma. Sci Rep. 2016;6:38834.

[17] Shih CH, Chang YJ, Huang WC, et al. EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis. Oncogene. 2017;36(47):6542-6554.

[18] Hao Y, Xiao Y, Liao X, et al. FGF8 induces epithelial-mesenchymal transition and promotes metastasis in oral squamous cell carcinoma. Int J Oral Sci. 2021;13(1):6.

[19] Horny K, Sproll C, Peiffer L, et al. Mesenchymal–epithelial transition in lymph node metastases of oral squamous cell carcinoma is accompanied by ZEB1 expression. J Transl Med. 2023;21(1):267.

[20] Ji X, Sun T, Xie S, et al. Upregulation of CPNE7 in mesenchymal stromal cells promotes oral squamous cell carcinoma metastasis through the NF-κB pathway. Cell Death Discov. 2021;7(1):294.

[21] Cui B, Chen J, Luo M, et al. PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling. Int J Oral Sci. 2021;13(1):8.

[22] Pidugu VK, Wu MM, Yen AH, et al. IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling. Oncogene. 2019;38(17):3232-3247.

[23] Liu ZL, Meng XY, Bao RJ, et al. Single cell deciphering of progression trajectories of the tumor ecosystem in head and neck cancer. Nature Commun. 2024;15(1):2595.

[24] Choi J-H, Lee B-S, Jang JY, et al. Single-cell transcriptome profiling of the stepwise progression of head and neck cancer. Nature Commun. 2023;14(1):1055.

[25] Eric H, Piersiala K, Lagebro V, et al. High expression of PD-L1 on conventional dendritic cells in tumour-draining lymph nodes is associated with poor prognosis in oral cancer. Cancer Immunol, Immunother. 2024;73(9):165.

[26] Rahim MK, Okholm TLH, Jones KB, et al. Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023;186(6):1127-1143.e18.

[27] Melo-Alvim C, Neves ME, Santos JL, et al. Radiotherapy, chemotherapy and immunotherapy-current practice and future perspectives for recurrent/metastatic oral cavity squamous cell carcinoma. Diagnostics (Basel). 2022;13(1):99.

[28] Bhat GR, Sethi I, Sadida HQ, et al. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metast Rev. 2024;43(1):197-228.

[29] Pickering CR, Zhang J, Yoo SY, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013;3(7):770-781.

[30] Gillison ML, Akagi K, Xiao W, et al. Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. Genome Res. 2019;29(1):1-17.

[31] Sequeira I, Rashid M, Tomás IM, et al. Genomic landscape and clonal architecture of mouse oral squamous cell carcinomas dictate tumour ecology. Nature Commun. 2020;11(1):5671.

[32] Tan Y, Wang Z, Xu M, et al. Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci. 2023;15(1):44.

[33] Shridhar K, Walia GK, Aggarwal A, et al. DNA methylation markers for oral pre-cancer progression: a critical review. Oral Oncol. 2016;53:1-9.

[34] Elmusrati A, Wang J, Wang CY. Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci. 2021;13(1):24.

[35] Pour M, Yanai I. New adventures in spatial transcriptomics. Dev Cell. 2022;57(10):1209-1210.

[36] Wu D, Liu X, Zhang J, Li L, Wang X. Significance of single-cell and spatial transcriptomes in cell biology and toxicology. Cell Biol Toxicol. 2021;37(1):1-5.

[37] Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99.

[38] Ji H, Hu C, Yang X, et al. Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. Signal Transduct Targeted Ther. 2023;8(1):367.

[39] Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576-582.

[40] Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, Lichtenstein L. Calling somatic SNVs and indels with Mutect2. bioRxiv. 2019:861054.

[41] Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808-1825.

[42] Mroz EA, Rocco JW. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol. 2013;49(3):211-215.

[43] Zhao Q, Zheng H, Duan W, et al. Association between MUC5B mutation and prognosis across solid tumors. J Clin Oncol. 2020;38(15_suppl):e13515.

[44] Jiang X, He Y, Shen Q, et al. RETSAT mutation selected for hypoxia adaptation inhibits tumor growth. Front Cell Dev Biol. 2021;9:744992.

[45] Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Targeted Therapy. 2023;8(1):92.

[46] Liang J, Fan J, Wang M, et al. CDKN2A inhibits formation of homotypic cell-in-cell structures. Oncogenesis. 2018;7(6):50.

[47] Sondka Z, Dhir NB, Carvalho-Silva D, et al. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucl Acids Res. 2023;52(D1):D1210-D1217.

[48] Li X, He Y, Wu J, et al. A novel pathway mutation perturbation score predicts the clinical outcomes of immunotherapy. Brief Bioinformat. 2022;23(5):bbac360.

[49] Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol. 2003;3(1):36-50.

[50] Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.

[51] Chang X, Zhao Y, Hou C, et al. Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk. Nat Commun. 2017;8(1):569.

[52] Dubard Gault M, Mandelker D, DeLair D, et al. Germline SDHA mutations in children and adults with cancer. Cold Spring Harb Mol Case Stud. 2018;4(4):a002584.

[53] Li J, Peng Y. Knockdown RPL29 gene can inhibit the proliferation, invasion of squamous cell carcinomas. Ann Clin Lab Sci. 2019;49(6):763-769.

[54] Shi M, Huang K, Wei J, et al. Identification and validation of a prognostic signature derived from the cancer stem cells for oral squamous cell carcinoma. Int J Mol Sci. 2024;25(2):1031.

[55] Xie J-M, Li B, Yu H-P, et al. TIGAR has a dual role in cancer cell survival through regulating apoptosis and autophagy. Cancer Res. 2014;74(18):5127-5138.

[56] Li Y, Wan Q, Wang W, et al. LncRNA ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation, migration and EMT via the miR-600/EZH2 axis. Biomed Pharmacother. 2019;112:108719.

[57] Bruckman KC, Schönleben F, Qiu W, Woo VL, Su GH. Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(5):632-637.

[58] Hartanto FK, Karen-Ng LP, Vincent-Chong VK, et al. KRT13, FAIM2 and CYP2W1 mRNA expression in oral squamous cell carcinoma patients with risk habits. Asian Pac J Cancer Prev. 2015;16(3):953-958.

[59] Guan C, Ouyang D, Qiao Y, et al. CA9 transcriptional expression determines prognosis and tumour grade in tongue squamous cell carcinoma patients. J Cell Mol Med. 2020;24(10):5832-5841.

[60] Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 1996;2(6):682-685.

[61] Bhosale PG, Pandey M, Cristea S, et al. Recurring amplification at 11q22.1-q22.2 locus plays an important role in lymph node metastasis and radioresistance in OSCC. Sci Rep. 2017;7(1):16051.

[62] Dong A, Wodziak D, Lowe AW. Epidermal Growth factor receptor (EGFR) signaling requires a specific endoplasmic reticulum thioredoxin for the post-translational control of receptor presentation to the cell surface. J Biol Chem. 2015;290(13):8016-8027.

[63] Wodziak D, Dong A, Basin MF, Lowe AW. Anterior Gradient 2 (AGR2) induced epidermal growth factor receptor (EGFR) signaling is essential for murine pancreatitis-associated tissue regeneration. PLoS One. 2016;11(10):e0164968.

[64] Lecker LSM, Berlato C, Maniati E, et al. TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer. Cancer Res. 2021;81(22):5706-5719.

[65] Yokobori T, Nishiyama M. TGF-β signaling in gastrointestinal cancers: progress in basic and clinical research. J Clin Med. 2017;6(1):11.

[66] Yoo H-J, Yun B-R, Kwon J-H, et al. Genetic and expression alterations in association with the sarcomatous change of cholangiocarcinoma cells. Exp Mol Med. 2009;41(2):102-115.

[67] Mou PK, Yang EJ, Shi C, Ren G, Tao S, Shim JS. Aurora kinase A, a synthetic lethal target for precision cancer medicine. Exp Mol Med. 2021;53(5):835-847.

[68] Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417-425.

[69] Garofano L, Migliozzi S, Oh YT, et al. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer. 2021;2(2):141-156.

[70] Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102(43):15545-15550.

[71] Löbrich M, Jeggo PA. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer. 2007;7(11):861-869.

[72] Segeren HA, van Rijnberk LM, Moreno E, et al. Excessive E2F transcription in single cancer cells precludes transient cell-cycle exit after DNA damage. Cell Reports. 2020;33(9):108449.

[73] Kerseviciute I, Gordevicius J. aPEAR: an R package for autonomous visualization of pathway enrichment networks. Bioinformatics. 2023;39(11):btad672.

[74] Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243-259.

[75] Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nature Commun. 2013;4(1):2612.

[76] Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.

[77] Fraga M, Yáñez M, Sherman M, et al. Immunomodulation of T helper cells by tumor microenvironment in oral cancer is associated with CCR8 expression and rapid membrane vitamin D signaling pathway. Front Immunol. 2021;12:643298.

[78] Feng Q, Wei H, Morihara J, et al. Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol. 2012;127(2):412-419.

[79] Alam A, Levanduski E, Denz P, et al. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell. 2022;40(2):153-167.e11.

[80] Fässler M, Diem S, Mangana J, et al. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer. 2019;7(1):50.

[81] Chen Y, Sun J, Luo Y, et al. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer. J Transl Med. 2022;20(1):615.

[82] Chen Y, Zhao H, Feng Y, et al. Pan-cancer analysis of the associations of TGFBI expression with prognosis and immune characteristics. Front Mol Biosci. 2021;8:745649.

[83] Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteom. 2012;11(6):O111.016717.

[84] Qiu M, Lin Q, Liu Y, et al. Potentially functional genetic variants in RPS6KA4 and MAP2K5 in the MAPK signaling pathway predict HBV-related hepatocellular carcinoma survival. Mol Carcinog. 2023;62(9):1378-1387.

[85] Chen G, Sun J, Xie M, Yu S, Tang Q, Chen L. PLAU promotes cell proliferation and epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Front Genet. 2021;12:651882.

[86] Szalmás A, Tomaić V, Basukala O, et al. The PTPN14 tumor suppressor is a degradation target of human papillomavirus E7. J Virol. 2017;91(7):e00057-17.

[87] Yuan Z, Li Y, Zhang S, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22(1):48.

[88] Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9(1):559.

[89] AmeliMojarad M, AmeliMojarad M, Cui X, Shariati P. Pan-cancer analysis of CTNNB1 with potential as a therapeutic target for human tumorigenesis. Informat Med Unlock. 2023;42:101331.

[90] van Schie EH, van Amerongen R. Aberrant WNT/CTNNB1 signaling as a therapeutic target in human breast cancer: weighing the evidence. Front Cell Dev Biol. 2020;8:25.

[91] Thomas de Montpréville V, Lacroix L, Rouleau E, et al. Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: a clinicopathological study of 26 cases. Ann Diagn Pathol. 2020;46:151522.

[92] Hema KN, Smitha T, Sheethal HS, Mirnalini SA. Epigenetics in oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2017;21(2):252-259.

[93] Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell. 2007;128(4):635-638.

[94] Basu B, Chakraborty J, Chandra A, et al. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India. Clin Epigenetics. 2017;9:13.

[95] Xu Z, Qin F, Yuan L, et al. EGFR DNA methylation correlates with EGFR expression, immune cell infiltration, and overall survival in lung adenocarcinoma. Front Oncol. 2021;11:691915.

[96] Liu AY, Zheng H, Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol. 2014;37:150-156.

[97] Bessa X, Elizalde JI, Mitjans F, et al. Leukocyte recruitment in colon cancer: role of cell adhesion molecules, nitric oxide, and transforming growth factor beta1. Gastroenterology. 2002;122(4):1122-1132.

[98] Liao J, Chen R, Lin B, et al. Cross-talk between the TGF-β and cell adhesion signaling pathways in cancer. Int J Med Sci. 2024;21(7):1307-1320.

[99] Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328-337.

[100] Weinberg RA. Coming full circle-from endless complexity to simplicity and back again. Cell. 2014;157(1):267-271.

[101] Navin NE. The first five years of single-cell cancer genomics and beyond. Genome Res. 2015;25(10):1499-1507.

[102] Tanay A, Regev A. Scaling single-cell genomics from phenomenology to mechanism. Nature. 2017;541(7637):331-338.

[103] Gao R, Bai S, Henderson YC, et al. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat Biotechnol. 2021;39(5):599-608.

[104] Wright K, Ly T, Kriet M, Czirok A, Thomas SM. Cancer-associated fibroblasts: master tumor microenvironment modifiers. Cancers (Basel). 2023;15(6):1899.

[105] Li X, Wang C-Y. From bulk, single-cell to spatial RNA sequencing. Int J Oral Sci. 2021;13(1):36.

[106] Williams CG, Lee HJ, Asatsuma T, Vento-Tormo R, Haque A. An introduction to spatial transcriptomics for biomedical research. Gen Med. 2022;14(1):68.

[107] Oral cancer – the fight must go on against all odds.... Evid-Based Dent. 2022;23(1):4-5.

[108] Parmar A, Macluskey M, Mc Goldrick N, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev. 2021;12(12):Cd006386.

[109] Gamez ME, Kraus R, Hinni ML, et al. Treatment outcomes of squamous cell carcinoma of the oral cavity in young adults. Oral Oncol. 2018;87:43-48.

[110] Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450-462.

[111] Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Gen. 2012;13(4):227-232.

[112] Chen YJ, Roumeliotis TI, Chang YH, et al. Proteogenomics of non-smoking lung cancer in east asia delineates molecular signatures of pathogenesis and progression. Cell. 2020;182(1):226-244.e17.

[113] Altelaar AF, Munoz J, Heck AJ. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet. 2013;14(1):35-48.

[114] Hanash S. Disease proteomics. Nature. 2003;422(6928):226-232.

[115] Mani DR, Krug K, Zhang B, et al. Cancer proteogenomics: current impact and future prospects. Nat Rev Cancer. 2022;22(5):298-313.

[116] Rodriguez H, Zenklusen JC, Staudt LM, Doroshow JH, Lowy DR. The next horizon in precision oncology: proteogenomics to inform cancer diagnosis and treatment. Cell. 2021;184(7):1661-1670.

[117] Popova NV, Jücker M. The functional role of extracellular matrix proteins in cancer. Cancers (Basel). 2022;14(1):238.

[118] Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nature Commun. 2018;9(1):4692.

[119] Hinz B. The extracellular matrix and transforming growth factor-β1: tale of a strained relationship. Matrix Biol. 2015;47:54-65.

[120] Wang BJ, Chi KP, Shen RL, et al. TGFBI promotes tumor growth and is associated with poor prognosis in oral squamous cell carcinoma. J Cancer. 2019;10(20):4902-4912.

[121] Ahmed AA, Mills AD, Ibrahim AE, et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007;12(6):514-527.

[122] Reticker-Flynn NE, Zhang W, Belk JA, et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell. 2022;185(11):1924-1942.e23.

[123] Peng JM, Su YL. Lymph node metastasis and tumor-educated immune tolerance: Potential therapeutic targets against distant metastasis. Biochem Pharmacol. 2023;215:115731.

[124] Liu Z, Zhang Z, Zhang Y, et al. Spatial transcriptomics reveals that metabolic characteristics define the tumor immunosuppression microenvironment via iCAF transformation in oral squamous cell carcinoma. Int J Oral Sci. 2024;16(1):9.

[125] Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000;100(1):57-70.

[126] Miao D, Margolis CA, Vokes NI, et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Gen. 2018;50(9):1271-1281.

[127] Suski JM, Braun M, Strmiska V, Sicinski P. Targeting cell-cycle machinery in cancer. Cancer Cell. 2021;39(6):759-778.

[128] Castro-Gamero AM, Pezuk JA, Brassesco MS, Tone LG. G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future. Cancer Biol Med. 2018;15(4):354-374.

[129] Dorafshan S, Razmi M, Safaei S, Gentilin E, Madjd Z, Ghods R. Periostin: biology and function in cancer. Cancer Cell Int. 2022;22(1):315.

[130] Xu C, Wang Z, Zhang L, et al. Periostin promotes the proliferation and metastasis of osteosarcoma by increasing cell survival and activates the PI3K/Akt pathway. Cancer Cell Int. 2022;22(1):34.

[131] Chen L, Tian X, Gong W, et al. Periostin mediates epithelial-mesenchymal transition through the MAPK/ERK pathway in hepatoblastoma. Cancer Biol Med. 2019;16(1):89-100.

[132] Chen Y, Zhang F, Zhang B, et al. Periostin is associated with prognosis and immune cell infiltration in pancreatic adenocarcinoma based on integrated bioinformatics analysis. Cancer Rep. 2024;7(2):e1990.

[133] Gao F, Liu J, Gan H. The expression of POSTN and immune cell infiltration are prognostic factors of lung adenocarcinoma. Medicine (Baltimore). 2022;101(34):e30187.

[134] Hu C, Zhang Y, Wu C, Huang Q. Heterogeneity of cancer-associated fibroblasts in head and neck squamous cell carcinoma: opportunities and challenges. Cell Death Discov. 2023;9(1):124.

[135] Li X, González-Maroto C, Tavassoli M. Crosstalk between CAFs and tumour cells in head and neck cancer. Cell Death Discov. 2024;10(1):303.

[136] Chen C, Guo Q, Liu Y, et al. Single-cell and spatial transcriptomics reveal POSTN+ cancer-associated fibroblasts correlated with immune suppression and tumour progression in non-small cell lung cancer. Clin Transl Med. 2023;13(12):e1515.

[137] Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Gen Med. 2017;9(1):34.

[138] Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLOS Comput Biol. 2016;12(4):e1004873.

[139] Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Prot. 2016;11(9):1650-1667.

[140] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284-287.

[141] Jiao X, Sherman BT, da Huang W, et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics. 2012;28(13):1805-1806.

[142] Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605-d12.

[143] Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504.

[144] Tian Y, Morris TJ, Webster AP, et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics. 2017;33(24):3982-3984.

[145] Phipson B, Maksimovic J, Oshlack A. missMethyl: an R package for analyzing data from Illumina’s HumanMethylation450 platform. Bioinformatics. 2016;32(2):286-288.

[146] Park J, Kim J, Kim E, Kim WJ, Won S. Prenatal lead exposure and cord blood DNA methylation in the Korean Exposome Study. Environ Res. 2021;195:110767.

[147] Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019;47(W1):W199-w205.

[148] Alkaslasi MR, Piccus ZE, Hareendran S, et al. Single nucleus RNA-sequencing defines unexpected diversity of cholinergic neuron types in the adult mouse spinal cord. Nature Commun. 2021;12(1):2471.

[149] Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413.

[150] Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33(5):495-502.

[151] Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888-1902.e21.

[152] Hu C, Li T, Xu Y, et al. CellMarker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data. Nucl Acids Res. 2022;51(D1):D870-D876.

[153] Jin S, Guerrero-Juarez CF, Zhang L, et al. Inference and analysis of cell-cell communication using CellChat. Nature Commun. 2021;12(1):1088.

[154] Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinform. 2013;14(1):7.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.